Janet Legare, MD

Position title: Professor

Division of Genetics & Metabolism
Division of Developmental Pediatrics & Rehabilitative Medicine
For Academic Inquiries: (608) 263-8663


BS, University of Wisconsin–Madison, Madison, Wisconsin
MD, University of Wisconsin Medical School, Madison, Wisconsin
Residency, Pediatrics, The Children’s Hospital and University of Colorado, School of Medicine, Denver, Colorado
Residency, Physical Medicine and Rehabilitation, University of Colorado, School of Medicine, Denver, Colorado

Professional Activities

Dr. Janet Legare serves as professor (CT) in the Divisions of Genetics and Metabolism and Developmental Pediatrics and Rehabilitative Medicine. Legare serves as director of both the Midwest Regional Bone Dysplasia Clinic and the Neuromotor Development Clinic, both affiliated with UW Health Kids.

Legare actively engages with various professional societies, including the American Academy of Pediatrics, Society for Pediatric Research, American college of Medical Genetics, and Little People of America. She is also actively involved in the International Skeletal Dysplasia Society. At the department level, she is a member of the Inclusion, Diversity, Equity, Accessibility, and Anti-Racism (IDEAA) Committee.

Clinical Interests

Legare’s clinical expertise encompasses diagnosis, management, and ongoing care for children with various types of skeletal dysplasia. She also is actively involved in management of children with other genetic neurological and cognitive diagnoses such as Rett syndrome, Trisomy 18, Angelman syndrome etc. She is a leader in multidisciplinary care.

Research Interests

Legare’s research focuses on pediatric conditions, particularly achondroplasia and skeletal dysplasia. Her research aims to elucidate the natural history of these conditions, assess treatment options, and enhance patient care. She is a site PI for multiple clinical trials for achondroplasia including multicenter observational studies and clinical trials sponsored by organizations such as Ascendis Pharma and BridgeBio Pharma.